Crestline Management, LP

Q2 2018 13F Combination Report, Stock Holdings

Signature - Title
John S. Cochran - Vice President
Location
Fort Worth
Holdings as of
June 30, 2018
Value $
$952M
Num holdings
228
Date filed
8/14/2018, 11:26 AM
Form type
13F-HR
Description
A portion of the US holdings for this investor are reported in this report and a portion are reported by other reporting manager(s). Top holdings included DNLI, ATH, AMG, INFO, and JEF.
Previous filing
Q1 2018 - May 15, 2018
Sym Weight Trade Impact Company Class Shares Change Activity Value Change $ Value $ * Price $ Shares Principal
Filing 2018 Q2 compared to 2018 Q1 by default.
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.

Person Signing this Report on Behalf of Reporting Manager:

Name Title City, State Date
John S. Cochran Vice President Fort Worth, Texas 8/14/2018

The number of shares in Denali Therapeutics Inc. reflected herein includes 1,111,798 shares held by Neuro Line Partners, L.P. over which Bratton Capital Management, L.P. and Bratton Capital, Inc. have investment discretion. Mr. Bratton has ultimate investment discretion over Bratton Capital Management, L.P., Bratton Capital, Inc. and Crestline Management, L.P.

List of Other Managers Reporting for Crestline Management, LP:

Name Holdings Value Location File Number
Sector Gamma As $403M Oslo, Norway 028-13612
Interval Partners, LP $4.67B New York, NY 028-16003
Oribel Capital Management, LP $856M New York, NY 028-17769
Blackstart Capital LP $147M New York, NY 028-17673
TVR Capital Management LP $5.44M Stamford, CT 028-17837
Lucha Capital Management, LP $327M San Francisco, CA 028-17855
Bay Street Capital Partners LLC $81.9M New York, NY 028-18434
Azora Capital LP $2.16B Miami, FL 028-18527
Breogan Capital, LP $52.2M New York, NY 028-18442